Acitretin Topical Gel Solubility and Release Mechanism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis, including topical and systemic therapies, face challenges such as limited efficacy, severe side effects, high costs, and irritancy to the skin, making them unsuitable for long-term use, particularly due to the poor solubility and systemic side effects of acitretin, which is typically administered orally.
Innovation Solution
A stable topical pharmaceutical composition of acitretin is developed in the form of a gel, using a combination of gelling agents, solvents, and co-solvents like diethylene glycol monoethyl ether and dimethyl isosorbide, which increases acitretin's solubility up to 10,000 times and facilitates its release into the skin, minimizing systemic side effects and skin irritancy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acitretin is administered orally for treating psoriasis, then therapeutic efficacy is achieved, but systemic side effects occur
Solution Approach 1:
The invention extracts the active ingredient acitretin from its conventional oral dosage form and delivers it specifically to the target site (skin) through topical application. This localization extracts the therapeutic effect from the systemic circulation, achieving psoriasis treatment while minimizing systemic side effects.
Solution Approach 2:
The invention uses a topical gel formulation as an intermediary vehicle to deliver acitretin directly to the skin. This intermediary system enables localized drug delivery, allowing the drug to act on the target organ (skin) without requiring systemic absorption, thereby reducing systemic side effects while maintaining therapeutic efficacy.
2Object-affected harmful factors
If topical retinoid compositions are used for treating skin disorders, then skin irritation is reduced compared to oral administration, but solubility of the drug remains poor
Solution Approach 1:
The invention changes the physical-chemical parameters of the formulation by using co-solvents and surfactants to enhance the solubility of acitretin in the topical gel. This parameter modification allows adequate drug dissolution and release while maintaining the topical route that reduces skin irritation compared to oral administration.
Solution Approach 2:
The invention employs a composite gel formulation containing multiple components including gelling agents, co-solvents, and surfactants that work synergistically. This composite material system addresses the solubility issue of acitretin while maintaining the benefits of topical application for reduced skin irritation.
3Ease of operation
If topical gel formulations are used for acitretin, then patient compliance improves due to reduced systemic side effects, but drug stability and solubilization become challenging
Solution Approach 1:
The topical gel formulation acts as an intermediary system that protects acitretin from degradation while enabling its delivery to the skin. The gel matrix and formulation components provide a stable environment for the drug, maintaining its integrity and effectiveness throughout the product shelf life, thereby supporting patient compliance.
Solution Approach 2:
The invention optimizes formulation parameters including pH, ionic strength, and composition ratios to enhance the stability of acitretin in the topical gel. These parameter adjustments prevent drug degradation and maintain consistent drug release, ensuring product stability that supports long-term patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical acitretin gel composition provides effective treatment for psoriasis with reduced irritancy and systemic side effects, improved patient compliance, and maintains stability for at least three months, with a mean in-vitro release rate that remains consistent over time, demonstrating enhanced solubilization and release of acitretin.
Implementation Method 1
using a combination of gelling agents, solvents, and co-solvents like diethylene glycol monoethyl ether and dimethyl isosorbide, which increases acitretin's solubility up to 10,000 times
Implementation Method 2
facilitates its release into the skin, minimizing systemic side effects and skin irritancy
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition.